XML 55 R44.htm IDEA: XBRL DOCUMENT v3.20.2

Segments (Tables)

6 Months Ended

Jun. 30, 2020

Segment Reporting [Abstract]

Information by Reportable Segment

Information by reportable segment was as follows:

			Three Months Ended June 30, 2020
			PGEN Therapeutics						ActoBio						MBP Titan						Trans Ova						Human Biotherapeutics						All Other						Total
Revenues from external customers			$	218					$	32					$	—					$	23,845					$	4,210					$	2,105					$	30,410
Intersegment revenues			1,612						(3)						—						90						—						—						1,699
Total segment revenues			$	1,830					$	29					$	—					$	23,935					$	4,210					$	2,105					$	32,109
Segment Adjusted EBITDA			$	(5,698)					$	(1,135)					$	(5,199)					$	6,528					$	(495)					$	637					$	(5,362)

			Three Months Ended June 30, 2019
			PGEN Therapeutics						ActoBio						MBP Titan						Trans Ova						Human Biotherapeutics						All Other						Total
Revenues from external customers			$	549					$	181					$	1,215					$	24,392					$	2,462					$	3,998					$	32,797
Intersegment revenues			2,412						52						2						674						—						60						3,200
Total segment revenues			$	2,961					$	233					$	1,217					$	25,066					$	2,462					$	4,058					$	35,997
Segment Adjusted EBITDA			$	(7,467)					$	(4,124)					$	(9,188)					$	4,932					$	(354)					$	(2,479)					$	(18,680)

			Six Months Ended June 30, 2020
			PGEN Therapeutics						ActoBio						MBP Titan						Trans Ova						Human Biotherapeutics						All Other						Total
Revenues from external customers			$	378					$	230					$	—					$	40,630					$	14,573					$	4,397					$	60,208
Intersegment revenues			3,715						(3)						7						199						—						281						4,199
Total segment revenues			$	4,093					$	227					$	7					$	40,829					$	14,573					$	4,678					$	64,407
Segment Adjusted EBITDA			$	(12,617)					$	(3,125)					$	(13,963)					$	5,329					$	(1,833)					$	1,129					$	(25,080)

			Six Months Ended June 30, 2019
			PGEN Therapeutics						ActoBio						MBP Titan						Trans Ova						Human Biotherapeutics						All Other						Total
Revenues from external customers			$	1,730					$	582					$	2,696					$	39,326					$	2,845					$	8,095					$	55,274
Intersegment revenues			4,777						495						2						947						—						73						6,294
Total segment revenues			$	6,507					$	1,077					$	2,698					$	40,273					$	2,845					$	8,168					$	61,568
Segment Adjusted EBITDA			$	(14,836)					$	(6,562)					$	(17,214)					$	2,706					$	(577)					$	(3,717)					$	(40,200)

Reconciliation of Operating Profit (Loss) from Segments to Consolidated

The table below reconciles total segment revenues from reportable segments to total consolidated revenues:

			Three Months Ended   June 30,																		Six Months Ended   June 30,
			2020						2019						2020						2019
Total segment revenues from reportable segments			$	30,004					$	31,939					$	59,729					$	53,400
Other revenues, including from other operating segments			2,526						4,097						5,740						8,315
Elimination of intersegment revenues			(2,106)						(3,200)						(5,207)						(6,294)
Total consolidated revenues			$	30,424					$	32,836					$	60,262					$	55,421

The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:

			Three Months Ended   June 30,																		Six Months Ended   June 30,
			2020						2019						2020						2019
Segment Adjusted EBITDA for reportable segments			$	(5,999)					$	(16,201)					$	(26,209)					$	(36,483)
All Other Segment Adjusted EBITDA			637						(2,479)						1,129						(3,717)
Remove cash paid for capital expenditures and investments in affiliates			1,879						4,155						4,620						7,667
Add recognition of previously deferred revenue associated with upfront and milestone payments			5,573						6,247						18,046						10,859
Other expenses:
Interest expense			(4,592)						(4,353)						(9,184)						(8,658)
Depreciation and amortization			(4,783)						(4,863)						(9,593)						(10,207)
Impairment losses			(22,041)						—						(22,041)						—
Stock-based compensation expense			(4,897)						484						(10,615)						(7,764)
Adjustment related to bonuses paid in equity awards			—						—						2,833						—
Equity in net loss of affiliates			(251)						(716)						(602)						(1,464)
Other			3						—						12						—
Unallocated corporate costs			(7,344)						(11,426)						(17,526)						(29,448)
Eliminations			(1,659)						(3,162)						(4,246)						(6,012)
Consolidated net loss from continuing operations before income taxes			$	(43,474)					$	(32,314)					$	(73,376)					$	(85,227)

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration